LFB Biotechnologies and GTC Biotherapeutics to Collaborate on rhAAT Program

FRAMINGHAM, Mass. & PARIS--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire francais du Fractionnement et des Biotechnologies S.A.) have agreed to include GTC’s recombinant human alpha-1 antitrypsin program in their strategic collaboration for the development of selected recombinant plasma proteins and monoclonal antibodies. In accordance with the existing collaboration agreement, LFB will be providing additional funding to support GTC’s work in the recombinant human alpha-1 antitrypsin program for 2008.

Back to news